The effect of ixekizumab treatment on MRI sacroiliac joint structural lesions in patients with radiographic axial spondyloarthritis: post-hoc analysis of a 52-week, randomised, placebo-controlled trial with an active reference arm
Lancet Rheumatol 2025;7: e314–22 DOI: 10.1016/S2665-9913(24)00312-6
Maksymowych et al. evaluated the effect of ixekizumab and adalimumab versus placebo over 52 weeks on structural lesions in sacroiliac joints assessed by MRI in patients naive to biological DMARDs with radiographic axSpA from the COAST-V study. The authors reported a decrease in erosion and increase in backfill at Week 16 with further reductions in erosion and increases in backfill occurring at Week 52 in patients receiving ixekizumab.
This first time post-hoc analysis included patients with MRI at baseline, 16 weeks, and 52 weeks. The analysis focused on the mean change in MRI structural lesions and further change in MRI structural lesions were analysed in subgroups of patients. The study highlighted that ixekizumab, like adalimumab, modifies structural lesions that is consistent with a rapid tissue response in patients with radiographic axSpA.
Keywords:
